Abpro Holdings (ABPO) Amortization of Deferred Charges (2024 - 2025)
Abpro Holdings' (ABPO) quarterly Amortization of Deferred Charges came in at -$258000.0 in Q4 2025, down 284.29% YoY from $140000.0 in Q4 2024, and down 288.32% on a QoQ basis from $137000.0 in Q3 2025.
Abpro Holdings (ABPO) Amortization of Deferred Charges (2024 - 2025) Analysis & Trends
Abpro Holdings (ABPO) has 2 years of Amortization of Deferred Charges data on file, last reported at -$258000.0 in Q4 2025.
- Quarterly Amortization of Deferred Charges fell 284.29% year-over-year to -$258000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $160000.0 (down 70.8% YoY) and the FY2025 annual result came in at $160000.0, down 70.8% from the prior year.
- Amortization of Deferred Charges eased to -$258000.0 in Q4 2025, from $137000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $144000.0 in Q1 2025 to a low of -$258000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -258,000.00 |
| Dec 31, 2025 | -258,000.00 |
| Sep 30, 2025 | 137,000.00 |
| Sep 30, 2025 | 137,000.00 |
| Jun 30, 2025 | 137,000.00 |
| Jun 30, 2025 | 137,000.00 |
| Mar 31, 2025 | 144,000.00 |
| Mar 31, 2025 | 144,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Mar 31, 2024 | 134,000.00 |
| Mar 31, 2024 | 134,000.00 |